$MRK News

Merck (MRK) Plans Early HIV Pill Licensing Across 129 Countries

Exploring Analyst Estimates for Merck (MRK) Q2 Earnings, Beyond Revenue and EPS

Merck (MRK) Stock Looks Cheap On Cash Flow But Fair On Earnings

Merck (MRK) Stock Moves -1.11%: What You Should Know

Merck Announces Fourth-Quarter 2026 Dividend

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Barclays Maintains Overweight on Merck & Co, Raises Price Target to $150

Earnings Preview: Merck (MRK) Q2 Earnings Expected to Decline

Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial

Merck (MRK) Is Up 5.4% After Expanding HIV PrEP Access And Launching Oral Cholesterol Drug

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Merck Announces Strategy For Rapid, Broad And Sustainable Access To Its HIV-1 Prevention Pill Alimatravir In Low- And Middle-Income Countries

Merck (MRK) Could Be 4% Undervalued As LIPFENDRA Approval Tests Its Premium Valuation

Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer

Merck (MRK) Declines More Than Market: Some Information for Investors

Merck (MRK) Wins FDA Approval For First Oral PCSK9 Cholesterol Drug